1. CSNK2B: A broad spectrum of neurodevelopmental disability and epilepsy severity.
- Author
-
Ernst ME, Baugh EH, Thomas A, Bier L, Lippa N, Stong N, Mulhern MS, Kushary S, Akman CI, Heinzen EL, Yeh R, Bi W, Hanchard NA, Burrage LC, Leduc MS, Chong JSC, Bend R, Lyons MJ, Lee JA, Suwannarat P, Brilstra E, Simon M, Koopmans M, van Binsbergen E, Groepper D, Fleischer J, Nava C, Keren B, Mignot C, Mathieu S, Mancini GMS, Madan-Khetarpal S, Infante EM, Bluvstein J, Seeley A, Bachman K, Klee EW, Schultz-Rogers LE, Hasadsri L, Barnett S, Ellingson MS, Ferber MJ, Narayanan V, Ramsey K, Rauch A, Joset P, Steindl K, Sheehan T, Poduri A, Vasquez A, Ruivenkamp C, White SM, Pais L, Monaghan KG, Goldstein DB, Sands TT, and Aggarwal V
- Subjects
- Adolescent, Adult, Age of Onset, Child, Child, Preschool, Developmental Disabilities physiopathology, Epilepsies, Myoclonic diagnosis, Epilepsies, Myoclonic etiology, Epilepsies, Myoclonic genetics, Epilepsy, Generalized diagnosis, Epilepsy, Generalized etiology, Exome genetics, Female, Genetic Variation, Humans, Infant, Intellectual Disability etiology, Intellectual Disability genetics, Male, Mutation genetics, Phenotype, Status Epilepticus diagnosis, Status Epilepticus etiology, Status Epilepticus genetics, Young Adult, Developmental Disabilities genetics, Epilepsy, Generalized genetics
- Abstract
CSNK2B has recently been implicated as a disease gene for neurodevelopmental disability (NDD) and epilepsy. Information about developmental outcomes has been limited by the young age and short follow-up for many of the previously reported cases, and further delineation of the spectrum of associated phenotypes is needed. We present 25 new patients with variants in CSNK2B and refine the associated NDD and epilepsy phenotypes. CSNK2B variants were identified by research or clinical exome sequencing, and investigators from different centers were connected via GeneMatcher. Most individuals had developmental delay and generalized epilepsy with onset in the first 2 years. However, we found a broad spectrum of phenotypic severity, ranging from early normal development with pharmacoresponsive seizures to profound intellectual disability with intractable epilepsy and recurrent refractory status epilepticus. These findings suggest that CSNK2B should be considered in the diagnostic evaluation of patients with a broad range of NDD with treatable or intractable seizures., (© 2021 International League Against Epilepsy.)
- Published
- 2021
- Full Text
- View/download PDF